Skip to content
Intended for US healthcare professionals.

Agent, daily dose and time to constipation: what two recent cohorts show

In a 2025 Japanese cohort of 63 adults with new weak-opioid exposure for chronic non-cancer pain, 49.2% met Rome IV criteria for opioid-induced constipation by day 14, while in an English hospital cohort of 80,475 adults without cancer, severe-constipation risk differed by agent and was highest at 50 to under 120 morphine milligram equivalents (MME) per day.

4 min read · 5 references · References retrieved 18 October 2026
Educational content for healthcare professionals. Not medical advice. AI-generated and not authored or reviewed by a licensed physician. Verify against current guidelines and product labeling before any clinical decision.

Two questions shape early assessment of opioid-induced constipation: which agents and daily doses carry higher risk, and how soon symptoms meet diagnostic criteria [1][2][3]. A 2026 German expert consensus notes that, unlike other opioid-related side effects, opioid-induced constipation usually does not improve over time [4].

What did the cohorts measure?

Severe constipation in a 2025 Northwest England hospital cohort of 80,475 adults without cancer was defined as administration of an enema or suppository after opioid exposure [1]. Two Japanese reports, a 2025 primary analysis and a 2026 post hoc analysis, covered the same 63 adults with new weak-opioid exposure for chronic non-cancer pain [2][3]. The 2025 report applied the Rome IV diagnostic criteria for opioid-induced constipation from day 7 and reported incidence at day 7 and day 14 [2]. The 2026 analysis assessed modified Rome IV criteria daily from day 1 to day 6 and reported onset at day 3 [3].

Do the agent and the daily dose change the risk?

Against codeine, the 2025 hospital cohort reported fully adjusted hazard ratios for severe constipation of 1.59 (95% CI 1.45 to 1.74) for morphine, 1.46 (95% CI 1.32 to 1.63) for oxycodone and 1.37 (95% CI 1.14 to 1.64) for fentanyl [1]. In that cohort, administration of more than one opioid concomitantly carried a hazard ratio of 1.85 (95% CI 1.66 to 2.06) relative to codeine [1]. Tramadol's hazard ratio relative to codeine was 0.80 (95% CI 0.64 to 1.00), a point estimate below codeine with an upper bound that reaches 1.00 [1].

Compared with under 50 MME per day, the 2025 hospital cohort found a hazard ratio of 1.95 (95% CI 1.78 to 2.15) at 50 to under 120 MME per day [1]. At 120 MME per day or more, that cohort's hazard ratio was 1.45 (95% CI 1.32 to 1.60), above the reference band but below the middle band [1]. The 2025 Japanese cohort, limited to 63 patients on weak opioids, found no association between Rome IV onset and dosage, or any demographic or clinical factor, in exploratory analyses [2].

How early does constipation appear?

In the 2025 Japanese cohort, cumulative incidence of opioid-induced constipation was 30.2% (95% CI 20.4 to 43.1) at the end of the first week and 49.2% (95% CI 37.7 to 62.1) by the end of the second week [2]. The 2026 post hoc analysis found that 23.8% of patients already met modified Rome IV criteria on day 3; this definition differs from the day 7 and day 14 figures, so they are not one curve [3].

Decreased defecation frequency is commonly used for diagnosis, yet the 2026 analysis found it in only 1.6% of patients at day 3 [3]. At day 3, lumpy or hard stools and self-awareness of constipation predicted onset by day 14 with positive predictive values of 70.0% and 72.7% in the 2026 analysis, against 49.2% incidence by day 14 in the 2025 report [2][3].

What do the consensus and guideline add?

The 2026 German consensus names validated tools such as the Bowel Function Index for diagnosis and monitoring [4]. The 2019 American Gastroenterological Association guideline places laxatives as first-line agents for opioid-induced constipation [5].

Where is the evidence uncertain?

The 2025 hospital cohort captured only in-hospital administration, and its enema or suppository outcome is a proxy for treated constipation, not Rome IV symptoms [1]. Authors employed by a manufacturer contributed to both Japanese reports [2][3]. The 2026 German consensus retained 12 of 15 draft statements at 90% agreement or more, and its funder, a pharmaceutical manufacturer, was involved in coordinating the board and the medical writing [4]. None of the 2025 and 2026 cohorts is from the United States [1][2][3].

At the point of care: what to check

  • Agent: which agent, and whether more than one is given together, given the hazard ratios the 2025 hospital cohort reported against codeine [1].
  • Daily dose band: which MME band applies, since the 2025 hospital cohort's hazard ratio was highest at 50 to under 120 MME per day [1].
  • Day-3 symptoms: whether lumpy or hard stools or self-awareness of constipation are present at day 3, the two early symptoms the 2026 analysis highlighted for predicting onset by day 14 [3].
  • Structured assessment: whether the Bowel Function Index, named in the funder-involved 2026 German consensus, is in use for monitoring [4].

References

  1. Yimer BB, Soomro M, McBeth J, et al. Comparative risk of severe constipation in patients treated with opioids for non-cancer pain: a retrospective cohort study in Northwest England. BMC Med. 2025;23(1):288. doi:10.1186/s12916-025-04118-7. https://pubmed.ncbi.nlm.nih.gov/40518524/ — accessed 18 October 2026.
  2. Hashimoto A, Morioka Y, Wada S, Koretaka Y, Sonohata M. Incidence of opioid-induced constipation in non-cancer patients using weak opioids for chronic pain in Japan: a cohort study. Sci Rep. 2025;15(1):17397. doi:10.1038/s41598-025-01770-0. https://pubmed.ncbi.nlm.nih.gov/40389568/ — accessed 18 October 2026.
  3. Morioka Y, Hashimoto A, Koretaka Y, Wada S, Sonohata M, Drewes AM. Early detection of opioid-induced constipation in patients initiating weak opioids for chronic non-cancer pain. Sci Rep. 2026;16(1):10605. doi:10.1038/s41598-026-45169-x. https://pubmed.ncbi.nlm.nih.gov/41912669/ — accessed 18 October 2026.
  4. Wobbe B, Andresen V, Baron R, et al. German expert consensus on opioid-induced constipation (OIC): recommendations and a treatment algorithm for clinical practice. J Clin Med. 2026;15(6):2369. doi:10.3390/jcm15062369. https://pubmed.ncbi.nlm.nih.gov/41899293/ — accessed 18 October 2026.
  5. Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019;156(1):218-226. doi:10.1053/j.gastro.2018.07.016. https://pubmed.ncbi.nlm.nih.gov/30340754/ — accessed 18 October 2026.

The clinical brief

One question, answered from the evidence

If this was useful, the newsletter arrives weekday mornings: about four minutes, with the source behind each figure.

By subscribing you attest that you are a licensed healthcare professional. We use your email and role only to send the clinical brief. See a sample issue · Privacy · Terms

Get the clinical brief in your inbox

Weekday mornings. One question, answered from the evidence.

  • Figures carry a numbered source
  • One question per issue — about four minutes
  • Unsubscribe from any email, in one click

19 articles · 120 references · 10 therapeutic areas · see a sample issue

By subscribing you attest that you are a licensed healthcare professional. We use your email and role only to send the clinical brief, and you can unsubscribe from any email. Your data is handled per our Privacy Policy and Terms.

We use cookies on this site
We use essential cookies to make the site work, and — only with your consent — analytics cookies to see which clinical topics are read. See our Cookie Policy.
Manage preferences